Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

344.00DKK
10:59am EDT
Change (% chg)

kr.-3.50 (-1.01%)
Prev Close
kr.347.50
Open
kr.347.35
Day's High
kr.347.45
Day's Low
kr.342.90
Volume
1,707,119
Avg. Vol
2,466,219
52-wk High
kr.349.70
52-wk Low
kr.265.15

Latest Key Developments (Source: Significant Developments)

Novo Nordisk: Securities Lawsuit Filed Against Novo Nordisk In Denmark
Friday, 16 Aug 2019 08:30am EDT 

Aug 16 (Reuters) - Novo Nordisk A/S ::HAS TODAY BEEN INFORMED THAT A SECURITIES LAWSUIT HAS BEEN FILED AGAINST COMPANY IN DENMARK.LAWSUIT IS FILED BY A NUMBER OF SHAREHOLDERS.LAWSUIT ALLEGES THAT NOVO NORDISK MADE MISLEADING STATEMENTS AND DID NOT MAKE APPROPRIATE DISCLOSURES REGARDING ITS SALES OF INSULIN PRODUCTS IN USA.CLAIM IS FOR A TOTAL AMOUNT OF DKK 11,785,192,218.DISAGREES WITH ALLEGATIONS AND IS PREPARED TO DEFEND COMPANY IN THIS MATTER.  Full Article

E-Therapeutics Says Extends Research Collaboration with Novo Nordisk
Thursday, 1 Aug 2019 02:00am EDT 

Aug 1 (Reuters) - E-Therapeutics PLC ::E-THERAPEUTICS PLC SAYS EXTENDS RESEARCH COLLABORATION WITH NOVO NORDISK AND SIGNS FIRST AGREEMENT ON ITS NEW GAINS FUNCTIONAL GENOMICS TECHNOLOGY.E-THERAPEUTICS PLC SAYS AMENDMENT EXTENDS ORIGINAL CONTRACT BY SIX MONTHS TO JUNE 2020.E-THERAPEUTICS PLC SAYS NOVO NORDISK HAS OPTION TO LICENSE RELEVANT IP GENERATED UNDER COLLABORATION.  Full Article

Novo Nordisk Says Brexit Contingency Plans Not Affected By Appointment Of New PM
Tuesday, 23 Jul 2019 07:18am EDT 

July 23 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK SAYS IS COMMITTED TO ENSURING PATIENTS’ MEDICINE SUPPLIES ARE UNAFFECTED WHATEVER THE OUTCOME OF BREXIT.NOVO NORDISK SAYS OUR PLANS FOR THIS HAVE NOT BEEN AFFECTED BY THE APPOINTMENT OF THE NEW PRIME MINISTER.NOVO NORDISK SAYS WE HAVE INCREASED OUR STOCK LEVELS AND NOW HAVE AROUND TWO AND A HALF TIMES OUR NORMAL STOCK (ROUGHLY 18 WEEKS’ WORTH) WHICH IS MORE THAN THE 6 WEEKS REQUESTED BY THE GOVERNMENT.  Full Article

Novo Nordisk Canada says ESPEROCT Is Now Approved In Canada
Friday, 12 Jul 2019 07:00am EDT 

July 12 (Reuters) - Novo Nordisk Canada Inc::ESPEROCT® IS NOW APPROVED IN CANADA FOR THE TREATMENT OF HEMOPHILIA A IN BOTH CHILDREN AND ADULTS.  Full Article

Novo Nordisk Announced That European Commission Has Granted Marketing Authorisation For Esperoct
Thursday, 20 Jun 2019 12:49pm EDT 

June 20 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK TODAY ANNOUNCED THAT EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORISATION FOR ESPEROCT.AUTHORISATION COVERS ALL 28 EUROPEAN UNION MEMBER STATES.NOVO NORDISK EXPECTS TO LAUNCH ESPEROCT IN FIRST EUROPEAN COUNTRIES DURING SECOND HALF OF 2019.  Full Article

Oxford Biomedica Says Novo Holdings Agreed To Invest Up To £53.5 Mln In Group
Tuesday, 28 May 2019 02:01am EDT 

May 28 (Reuters) - Novo Nordisk A/S ::OXFORD BIOMEDICA - NOVO HOLDINGS A/S AGREED TO INVEST UP TO £53.5 MILLION IN GROUP.OXFORD BIOMEDICA - NOVO HOLDINGS' INVESTMENT IN RETURN FOR NEW ORDINARY SHARES REPRESENTING UP TO 10.1% OF OUTSTANDING SHARES AFTER CAPITAL INCREASE.OXFORD BIOMEDICA PLC - PROCEEDS FROM DEAL WILL BE USED TO REPAY EXISTING DEBT FACILITY WITH OAKTREE CAPITAL MANAGEMENT IN FULL.OXFORD BIOMEDICA - PROCEEDS FROM DEAL WILL ALSO BE USED TO TO FURTHER DEVELOP LENTIVECTOR PLATFORM AND PROPRIETARY PRODUCT PORTFOLIO.  Full Article

Novo Nordisk To Present Data On Oral Semaglutide At ADA Conference
Wednesday, 22 May 2019 10:43am EDT 

May 22 (Reuters) - Novo Nordisk A/S ::SAYS NOVO NORDISK TO PRESENT DATA ON ORAL SEMAGLUTIDE AT 79TH ANNUAL AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS.SAYS RESULTS FROM SEVEN PHASE 3A PIONEER CLINICAL TRIALS FOR ORAL SEMAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES WILL BE PRESENTED INCLUDING CARDIOVASCULAR OUTCOMES TRIAL (PIONEER 6).  Full Article

Novo Nordisk CEO Says Fall In Victoza Sales Was As Expected
Friday, 3 May 2019 03:09am EDT 

May 3 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK CEO SAYS FALL IN VICTOZA SALES WAS AS EXPECTED.NOVO NORDISK CEO SAYS LAUNCH OF ORAL SEMAGLUTIDE EXPECTED IN 2020.NOVO NORDISK CFO SAYS OUR U.S. GLP-1 BUSINESS IS IMPACTED NEGATIVELY BY INVENTORY REDUCTIONS IN THE FIRST QUARTER.NOVO NORDISK CFO SAYS WHEN WE LOOK AT THE LIKE-FOR-LIKE PRICING WE ARE NOT SEEING ANY NET CHANGES IN PRICING IN THE GLP-1 SEGMENT IN THE U.S..  Full Article

Novo Nordisk Q1 Oper Profit Beats Expectations; Kepps Full-Year Guidance Unchanged
Friday, 3 May 2019 01:36am EDT 

May 3 (Reuters) - Novo Nordisk A/S ::Q1 SALES 29.3 BILLION DKK VERSUS 29.1 BILLION DKK SEEN IN REUTERS POLL.SAYS FOR 2019 OUTLOOK, SALES GROWTH IS STILL EXPECTED TO BE 2-5% AT CER, AND OPERATING PROFIT GROWTH IS STILL EXPECTED TO BE 2-6% AT CER.CEO SAYS WE DELIVERED VERY SOLID PERFORMANCE IN INTERNATIONAL OPERATIONS, DRIVEN BY SALES GROWTH IN ALL REGIONS, MEANWHILE, SALES IN USA WERE NEGATIVELY IMPACTED BY INVENTORY REDUCTIONS.CEO SAYS GLOBAL LAUNCH OF OZEMPIC(®), OUR NEW ONCE-WEEKLY GLP-1, IS WELL ON TRACK AND CONTINUES TO GAIN MARKET SHARE.CEO SAYS BASED ON PROGRESS WE MADE IN Q1 OF 2019, WE ARE ON TRACK TO DELIVER ON OUR OUTLOOK FOR FULL-YEAR.Q1 OPERATING PROFIT 14.2 BILLION DKK VERSUS 13.2 BILLION DKK SEEN IN REUTERS POLL.Q1 SALES OF OZEMPIC(®) WERE DKK 1,425 MILLION.SAYS GIVEN THE CURRENT EXCHANGE RATES VERSUS THE DANISH KRONE, SALES GROWTH REPORTED IN DKK IS NOW EXPECTED TO BE AROUND 5 PERCENTAGE POINTS HIGHER THAN AT CER IN 2019.IN USA, NEW-TO-BRAND PRESCRIPTION MARKET SHARE FOR OZEMPIC(®) HAS NOW EXCEEDED 30% BRINGING NOVO NORDISK'S COMBINED GLP-1 NEW-TO-BRAND PRESCRIPTION MARKET SHARE TO 50%.SAYS FOR 2019, NOVO NORDISK NOW EXPECTS FINANCIAL ITEMS (NET) TO AMOUNT TO A LOSS OF AROUND DKK 3.3 BILLION, OFFSETTING THE POSITIVE CURRENCY IMPACT ON OPERATING PROFIT.SAYS FOR 2019, GIVEN THE CURRENT EXCHANGE RATES VERSUS THE DANISH KRONE, SALES GROWTH REPORTED IN DKK IS NOW EXPECTED TO BE AROUND 3 PERCENTAGE POINTS HIGHER THAN AT CER.  Full Article

Novo Nordisk To Achieve Target Of 100 Pct Renewable Power In Production By 2020
Tuesday, 30 Apr 2019 03:00am EDT 

April 30 (Reuters) - Novo Nordisk A/S ::SAYS NOVO NORDISK TO ACHIEVE TARGET OF 100% RENEWABLE POWER IN PRODUCTION AND LAUNCHES NEW AMBITION AIMING FOR ZERO ENVIRONMENTAL IMPACT.MAKES NEW INVESTMENT IN A 672-ACRE SOLAR PANEL INSTALLATION IN NORTH CAROLINA, US, WHICH WILL PROVIDE POWER TO NOVO NORDISK'S ENTIRE US OPERATIONS FROM EARLY 2020.SAYS NOVO NORDISK FURTHERMORE ANNOUNCED A NEW TARGET OF ACHIEVING ZERO CO(2) EMISSIONS FROM ALL OPERATIONS AND TRANSPORT BY 2030.  Full Article

Photo

Novo Nordisk contests Danish lawsuit claiming $1.75 billion

COPENHAGEN Danish insulin-maker Novo Nordisk said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement.